Utilizing a Clinical Utility Index in a Phase 2, Randomized, Bayesian Response-Adaptive Design to Study the Efficacy and Safety of Gepotidacin (GSK2140944) in Patients With Acute Bacterial Skin and Skin Structure Infections
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.